Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

Recruiting now · Phase 1

Conditions studied: Gastrointestinal Stromal Tumors

In brief

To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies

Key facts

Study ID

NCT07618377

Run by

Ono Pharmaceutical Co., Ltd.

People needed

10

Starts

2026-07-07

Expected to finish

2028-02-01

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a histologically confirmed diagnosis of GIST.
• Participants who are refractory or intolerant to treatment with at least imatinib, sunitinib, and regorafenib.
• Participants with at least one measurable lesion per the modified Response Evaluation Criteria in Solid Tumors (mRECIST) within 28 days prior to the first administration of the investigational product.
• Participants with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

You may not qualify if…

• Participants with a concomitant or prior history of severe hypersensitivity reactions to other tyrosine kinase inhibitors.
• Participants with uncontrolled diabetes mellitus.
• Participants with a systemic infection requiring treatment.

Where it is running

• National Cancer Center Hospital East — Kashiwa, Chiba, Japan (enrolling)
• National Cancer Center Hospital — Tokyo, Chuo-ku, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.